Kornimate/medical-research-clean huggingface dataset:
is perfusion index an indicator of block success in ultrasound-guided infraclavicular brachial plexus block

Conditions: Carpal Tunnel Syndrome; Perfusion Index

Summary: the infraclavicular nerve block, which is frequently preferred in upper extremity surgeries, provides additional advantages such as reduction in opioid consumption by providing analgesic effect in the postoperative period as welll. the success of peripheral nerve blocks is usually assessed by subjective feedback from the patient, and patient cooperation is needed. the aim of this study is to assess whether the perfusion index level, which can be measured noninvasively, can be a predictor of the infraclavicular block success.

thirty patients who were operated on for carpal tunnel syndrome under infraclavicular brachial plexus block were included in our study. after the procedure, at 10-minute intervals, the sensory block was assessed by a pinprick test, and the motor block was assessed by the ability to flex the hand and the forearm. in addition, pi and skin temperature were measured 0-10-20-30 minutes after the block and at postoperative 2, 4, and 6 hours. 30 minutes after the measurements, the surgical procedure was allowed to begin in patients with successful block.

Eligibility criteria:
inclusion criteria: * ages of 18-75 * patients who will diagnose with carpal tunnel syndrome by electroneuromyography (enmg), and will undergo unilateral surgery under elective conditions * asa i-ii-iii patients exclusion criteria: * patients who will refuse this method * neurological deficits, * diabetes mellitus, * local anesthetic allergy, * morbidly obese, * peripheral vascular disease, coronary artery disease, or coagulopathy

Keywords: infraclavicular block perfusion index ultrasonography block assessment
effects of touch on brain connectivity and metabolic biomarkers in preterm infants

Conditions: Preterm; Infant ALL; Premature; Disease

Summary: improving the quality of life of preterm children by 2035 is the top priority of worldwide health organisations, including the who. every year, 15 million preterm infants, particularly those under 32 weeks of age, are at significant risk of neurocognitive impairments with adverse health consequences (disability, developmental delay, disease), exacerbated by the lack of post-hospital care for newborns. intervening on the health of the preterm newborn through certain types of "touch" from its first days of life to activate its cutaneous senses permits, in reality, a significant improvement in the clinical state of the infant, hence promoting its growth, development, and social behaviour. in the neonatal period, during which significant neurological development occurs, tactile interactions and close physical proximity between infants and caregivers have significant short-term effects on the health of premature infants (weight gain, brain and vision development) and medium- to long-term effects on their development and expression of sociability. the likelihood that a premature newborn may develop attention and autism spectrum disorders, brain, gastrointestinal, and respiratory difficulties, as well as sleep disorders during the preschool years, is so high that clinical and social settings must prioritise care. utilizing functional magnetic resonance imaging (frmi), computerized electroencephalogram (eeg), and metabolomics, the research aims to explore the effects of touch, including physiotherapy and manual therapy (omt) approaches, on brain activity. this research intends to examine the impact of touch on premature infants' brain activity (physical biomarker) and metabolic activity (biological biomarker).


Eligibility criteria:
inclusion criteria: * preterm birth, between 32.0 and 33.6 weeks gestational age (ga); * absence of comorbidities that could affect the stability of vital parameters, and therefore represent a contraindication to the proposed intervention. comorbities include sepsis, pathologies pertaining to surgery, respiratory or cardiovascular instability, birth from a drug-addicted or hiv-positive mother) or known congenital pathologies; * obtaining informed consent for participation in this research project from parents or legal guardians. exclusion criteria: * preterm infants born before 32.0 weeks of ga and after 34 weeks and with respiratory and neurological pathologies and any additional comorbities. * children whose parents will not read and sign or in case of failure to obtain informed consent will be excluded from the study.
perfusion index predicts post-spinal hypotension in obese parturients for cesarean section

Conditions: Perfusion Index Predicts Post-spinal Hypotension

Summary: hypotension is a common adverse effect of spinal anesthesia during caesarean section especially in obese patients. the aim of this study is to find out the correlation between baseline pi and post spinal hypotension in obese parturient.

abstract background hypotension is a common adverse effect of spinal anesthesia during caesarean section especially in obese patients. the aim of this study is to find out the correlation between baseline pi and post spinal hypotension in obese parturient. methods after approval of ethical committee and written informed consent, fifty parturients aged between 18- 40 years, asa i and ii with term singleton pregnancies with bmi between 25 \&40 admitted for cesarean section under spinal anesthesia were recruited in this prospective, observational study. the primary outcome is the correlation between baseline perfusion index and post spinal hypotension. the secondary outcome is the correlation between bmi and the incidence of hypotension after spinal anesthesia. heart rate, blood pressure, perfusion index before and after spinal induction using masimo device, level of sensory block, dose of ephedrine required to correct hypotension, dose of atropine required to correct bradycardia, incidence of nausea, vomiting and shivering were recorded.

Eligibility criteria:
inclusion criteria: * fifty parturient * aged between 18- 40, * asa i and ii * with term singleton pregnancies * with 25 ≥ bmi≤ 40 * conducted for cesarean section under spinal anesthesia exclusion criteria: * emergency cases, * placenta previa, * preeclampsia, * cardiovascular and cerebrovascular diseases, * patient with contraindication for regional anesthesia * patient with peripheral vascular diseases as dvt.
assessment of the impact on the quality of life of surgically assisted maxillary expansion in adult patients followed for obstructive sleep apnea syndrome

Conditions: Obstructive Sleep Apnea

Summary: the research aims to assess the impact on quality of life of surgically maxillary expansion in adult patients followed for obstructive sleep apnea syndrome.

this assessment will be done using the following elements: * the score of the quebec sleep questionnaire (qsq), developed in 2004 by lacasse y. et al. this questionnaire is specific to sleep apnea and may be self-administered. the main interest of this questionnaire is to measure the change in quality of life over time. * the epworth scale score, developed in 1991 by murray w. john. this is a self-administered questionnaire developed to measure daytime sleepiness. * gender, age group, bmi * the radiological assessment * the results of polysomnography patients will be followed for a period of 1 year and one month after surgery. the protocol visits correspond to the rhythm of post-surgery follow-up consultations in current practice. these patients are followed by dr. pételle at saint-antoine hospital. during these visits, they will complete the quebec sleep questionnaire and the epworth scale, at baseline, at 3 months and then at 1 year.

Eligibility criteria:
inclusion criteria: * adult patients * with obstructive sleep apnea confirmed by polysomnography * surgical indication for surgically maxillary expansion exclusion criteria: * - patients refusing to participate in the survey having formulated their opposition * diabetes, * obesity (bmi\> 30) * failure to provide informed written consent * refusal or inability to return to all follow-up visits and sleep studies * patient pregnant or planning to become pregnant in the next 12 months or breastfeeding * surgical resection or radiation therapy for cancer or congenital malformations of the larynx, tongue or throat (note that some previous surgeries, such as uvulopalatopharyngoplasty (uppp), tonsillectomy or adenoidectomy, to remove obstructions related to obstructive sleep apnea are allowed) * obvious obstructions of the fixed upper airways (tumors, polyps or nasal obstruction) * patients who have undergone previous surgery on the mandible and / or maxilla, other than dental treatment. * patients included in another clinical study (excluding registers). * patients taking medicines such as opiates which may affect sleep, alertness or breathing

Keywords: obstructive sleep apnea quality of life surgically assisted rapid maxillary expansion distraction osteogenesis palatal expansion technique
comparison of once daily versus 8 hour dosing of gentamicin for the treatment of intrapartum chorioamnionitis

Conditions: Chorioamnionitis

Summary: to compare once daily versus 8 hour dosing of gentamicin for the treatment of chorioamnionitis.


Eligibility criteria:
inclusion criteria: - clinical diagnosis of chorioamnionitis exclusion criteria: - maternal renal disease, intrauterine fetal death, allergy to gentamicin
cardboard cot: prevention of moderate or severe hypothermia in preterm infants assigned to open crib

Conditions: Infant, Premature

Summary: infants with an estimated gestational age \< 36 6/7 weeks at delivery who have been in an incubator in the newborn icu for at least 24 hours in settings where an incubator is available, or who are delivered in a setting where an incubator is not available, will be randomized to either standard protocol of open crib or mylar-lined cardboard cot for the duration of the hospital stay. axillary temperatures will be taken 1 hr, 6 hrs, and 24 hours after being placed in the cot or crib, and then once every 24 hours. all other care is provided as standard of care.

following parental consent, preterm infants with an estimated gestational age \< 36 6/7 weeks at delivery who have been in an incubator in the newborn icu for at least 24 hours in settings where an incubator is available, or who are in the newborn icu in a setting where an incubator is not available, will be randomized to to transfer either standard protocol of open crib or mylar-lined cardboard cot when their temperatures are stable for transfer. the infants will remain in the cot or crib for the duration of the hospital stay. axillary temperatures will be taken 1 hr, 6 hrs, and 24 hours after being placed in the cot or crib, and then once every 24 hours. all other care is provided as standard of care, including who warm chain thermoregulation guidelines of early and exclusive breastfeeding, appropriate bundling and kangaroo mother care as continuously as possible. if at any point a babies becomes moderately (32.0-35.9° c) or severely hypothermic (\< 32.0° c), an extra blanket will be added to their bodies and a hat placed on their heads.

Eligibility criteria:
inclusion criteria: * estimated gestational age \< 36 6/7 weeks * hospitalized in the newborn icu at university teaching hospital * nursed in an incubator for at least 24 hours * thought to be ready to be weaned from incubator by the clinical staff exclusion criteria: * major congenital anomalies * requiring ongoing respiratory support * suspected sepsis

Keywords: hypothermia newborn
influence of hrs9531 on gastric emptying and pharmacokinetics of metformin, atorvastatin, warfarin, and digoxin in healthy subjects

Conditions: Type 2 Diabetes

Summary: the purpose of this study is to evaluate the influence of hrs9531 injection on gastric emptying and pharmacokinetics of metformin, atorvastatin, warfarin, and digoxin in healthy subjects.


Eligibility criteria:
inclusion criteria: 1. ability to understand the trial procedures and possible adverse events, be able and willing to provide a written informed consent; 2. male subjects aged 18-45 years on the date of signing informed consent (inclusive); 3. body weight ≥60 kg, body mass index (bmi) within the range of 24.0-35.0 kg/m2 (inclusive); 4. hba1c\<6.0%; 5. the subjects have no plans to have children and voluntarily take effective contraceptive measures from the time of signing the informed consent to 2 months after the last medication, and have no plans to donate eggs/sperm; the pregnancy test of female subjects with fertility must be negative. exclusion criteria: 1. chronic or severe medical history of the respiratory system, circulatory system, digestive system, urinary system, blood system, endocrine system, immune system, nervous system, mental system, etc., or those with existing systemic diseases mentioned above, and judged by the investigator to be unsuitable to participate in this study; 2. past history or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2 (men2), a history of pancreatitis or symptomatic gallbladder stones; 3. history of disease that increases the risk of bleeding; 4. surgery within 6 months prior to dosing, planned to undergo surgery during the study period; 5. participation in clinical trials of any drug or medical device in the 3 months or 5 half-lives, whichever longer, prior to dosing; 6. blood donation history or blood loss ≥400 ml within 3 months or ≥200 ml within 1 month before dosing, or received blood transfusion within 3 months before dosing; 7. hepatitis b surface antigen (hbsag), hiv antibody, hepatitis c virus antibody (hcvab), treponema pallidum specific antibody detection, positive; 8. abnormal laboratory test results or abnormal examinations considered unsuitable to participate in this trial; 9. history of hypoglycaemia; 10. history of syncope or vasovagal episodes, difficulty with blood collection, or an inability to tolerate venipuncture; 11. the investigator considers that the subject has any other factors that would make it inappropriate to participate in this study.
optimal timing of euploid day 6 blastocyst transfer in frozen hrt cycles, day 6 or day 7 of progesterone administration.

Conditions: Infertility; Fertility Issues; Infertility, Female

Summary: the goal of this study is to compare the difference in clinical pregnancy, miscarriage and livebirth rate between day 6 euploid blastocyst transfer on the 6th and the 7th day of progesterone exposure in hormonal replacement therapy (hrt) fet cycles. this prospective \& randomized study will only include euploid day 6 blastocysts. this will be the first prospective study of euploid day 6 blastocysts thereby excluding aneuploidy as a cause of miscarriage and implantation failure. the point of randomization will occur on the day of progesterone commencement.

traditionally the duration of progesterone exposure before embryo transfer has been considered equal for day 5 and day 6 embryos but this may not be the case and warrants further study. the optimal preparation of the endometrium in frozen embryo transfer (fet) cycles is yet to be determined. synchronization between the embryonic stage and the endometrial window of implantation (woi) is crucial and progesterone plays a critical role in the woi (1). data on the optimal route of administration, the dose and duration of progesterone supplementation before blastocyst transfer are inconsistent (2,3). in view of the current lack of evidence, this study will be of importance.

Eligibility criteria:
inclusion criteria: * women aged 18 years to 43 years. * having at least 1 euploid cryopreserved day 6 blastocyst of at least grade bb quality. * endometrial trilaminar appearance on the day of progesterone start exclusion criteria: * uterine abnormality * hydrosalpinx * asherman syndrome * any known contraindications or allergy to oral estradiol or progesterone. * intention to treat : exclusion factors : 1. spontaneous ovulation hrt cycle 2. discontinuation of hrt medication

Keywords: implantation infertility blastocyst hrt progesterone
rct: titanium vs fcz vs zirconia framework

Conditions: Dental Prosthesis Failure

Summary: in recent years, zirconia-based implant-supported bridge designs have begun to be used more and more as an alternative to metal ceramic bridges. another new material that has been introduced in the clinic is the high translucent monolithic zirconia, which has only been investigated a few follow-up studies with short follow up duration. the aim being to evaluate the clinical outcome of implant-anchored posterior bridges, made from 1. high-translucent monolithic zirconia, 2. zirconia ceramic with porcelain and 3. metal ceramics. the hypothesis is that high-translucent monolithic zirconia has lower rate of complications since surface porcelain veneering is not required. a total of 60 research subjects will be included in the study. patients in need of a permanent implant-supported bridge, located posterior of the canine in the upper or lower jaw will be asked for participation. each subject will be treated according to standard treatment protocols with implants from nobel biocare, the branemark implant system and then be randomly assigned to obtain one of the following three type of bridges. 20 research subjects will be included in each of the three study arms. the prosthetic treatment will be carried out according to standard clinic protocol. all research subjects will be evaluated after 1, 3, 5 years. x-rays and photos will be taken at the installation of the bridges and after 1 and 5 years of follow-up or more frequent, depending on individual indication of the patient and the associated standard clinical care protocol. personal data, implant survival, marginal bone loss and biological and technical complications related to the implants will be recorded. survival of the bridge, technical and biological complication related to the bridge will also be recorded


Eligibility criteria:
inclusion criteria: edentulous behind the canine in the maxilla or mandible * older than 18 years exclusion criteria: * younger than 18 years * active periodontitis
learning health system for asthma

Conditions: Asthma

Summary: this study forms an initial phase of work aimed at developing a learning health system (lhs), whereby data relating to asthma is extracted from patient electronic health records (ehrs) across scotland, analysed to explore variations in clinical practice and then shared with general practices to highlight any improvements that can be made so that they can better support people with asthma. if successful, the investigators hope to progress to the main quality improvement phase involving an increased number of practices and then incrementally build this up to cover the whole of scotland.

the uk has amongst the highest rates of asthma in the world as well as some of the poorest health outcomes from asthma. investigations into asthma deaths in the uk have found that the way patients were managed in the time leading up to their death could be improved significantly and half of asthma deaths are potentially avoidable. for most people with asthma, symptoms can come and go and sometimes be erratic. to prevent these symptoms, there is a window of opportunity to intervene with the appropriate care. this window occurs between when someone experiences early symptoms like night cough or wheeze and when they experience a full-blown asthma attack. most people with asthma receive care primarily in their general practice. general practices have a history of using health information technology to care for their patients. the use of this technology over time has resulted in the creation of rich electronic healthcare data. through this rich data there are opportunities to create a system whereby clinical management can be benchmarked and improvements highlighted. this study forms an initial phase of work aimed at developing a learning health system (lhs), whereby data relating to asthma is extracted from patient electronic health records (ehrs) across scotland, analysed to explore variations in clinical practice and then shared with general practices to highlight any improvements that can be made so that they can better support people with asthma. if successful, the investigators hope to progress to the main quality improvement phase involving an increased number of practices and then incrementally build this up to cover the whole of scotland.

Eligibility criteria:
inclusion criteria: • patients registered with general practices across scotland. exclusion criteria: * patients from general practices that do not to opt-in to the study. * patients with a read code recording dissent from use of their records for research purposes.
coverage of requirements after consumption of a nutritional formula in patients with chewing/swallowing problems.

Conditions: Deglutition Disorders; Nutritional Deficiency; Chew Problems; Swallowing Disorder

Summary: effect of a nutritional formula on the nutritional requirements in patients with chewing/swallowing problems during one month

30 patients will receive nutritional education and guidelines for the consumption of a completed shreded diet including 2 packets of 90 grams every day (one salted packet for lunch/dinner and one sweet packet for breakfast/afternoon snack) and recommendations for physical activity for one month. 30 patients will receive nutritional education, guidelines for the consumption of a completed shreded diet and recommendations for physical activity during one month.

Eligibility criteria:
inclusion criteria: * men and women over 18 years old. * individuals with chewing/swallowing disorder. * individuals well nourished or at malnutrition risk. * adequate cultural level and understanding of the clinical trial. * signed informed consent. exclusion criteria: * individuals with body mass index ≥40 kg/m2. * individuals with acute, severe or chronic disease without control. * individuals with major surgeries during the last month. * individuals with gastrointestinal surgery the last three months. * individuals with moderate/severe cognitive impairment. * individuals with severe malnutrition. * individuals with amyotrophic lateral sclerosis. * individuals who consume nutritional oral supplements seven days prior to the start of the study. * enteral or parenteral nutrition.

Keywords: deglutition disorders nutritional deficiency chew problems swallowing disorder nutritional formula nutritional oral supplement
is adaptive sbrt for prostate vs image-guided radiotherapy a true evolution (aspire)

Conditions: Localized Prostate Cancer; Stereotactic Body Radiotherapy

Summary: the aspire study is a phase iii randomized, single-center study designed to evaluate whether adaptive stereotactic body radiotherapy (sbrt) offers superior clinical benefits compared to standard image-guided sbrt for patients with localized prostate cancer. it aims to explore whether adaptive sbrt can improve urinary outcomes while maintaining effective cancer control. this interventional study is randomized, single-institution, and includes 320 participants with localized prostate cancer. patients will be stratified based on fractionation schedules (5 vs. 7 fractions), use of rectal spacers, androgen deprivation therapy (adt), and baseline alpha receptor antagonist use. participants will be randomized to receive either adaptive sbrt or standard image-guided sbrt, with both arms adhering to established dosing protocols. inclusion criteria includes an age greater than 18 years, diagnosed with localized prostate adenocarcinoma, and an ecog performance status of 0-1, eligible for prostate sbrt. the exclusion criteria includes patients who plan for elective nodal irradiation and contraindications to radiotherapy or mri (for mr-linac patients).


Eligibility criteria:
inclusion criteria: 1. age \>18 years 2. histologic diagnosis of prostate adenocarcinoma 3. localized prostate cancer 4. low risk, intermediate risk, or high risk allowed 5. patient planned for prostate sbrt exclusion criteria: 1. planned for elective nodal irradiation 2. contraindications to radiotherapy